Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: a phase Ib, randomized, double-blind, placebo-controlled study
TLL-018 was well tolerated and showed promising efficacy at week 12 compared with placebo in patients with moderate-to-severe plaque psoriasis.
Authors
- Yuling Shi (ORCID: https://orcid.org/0000-0002-1273-7881)
- Tiechi Lei (ORCID: https://orcid.org/0000-0003-2304-827X)
- Xiaowei Shi (ORCID: https://orcid.org/0000-0002-0557-5810)
- Min Zheng (ORCID: https://orcid.org/0000-0001-9148-7544)
- Xiao‐Yong Man (ORCID: https://orcid.org/0000-0003-3331-5538)
- Jiaqi Chen (ORCID: https://orcid.org/0000-0002-0252-7987)
- Ping Wang (ORCID: https://orcid.org/0000-0002-2088-9279)
- Zhiming Li (ORCID: https://orcid.org/0000-0001-5589-1136)
- Yuzhen Li (ORCID: https://orcid.org/0000-0002-0312-5445)
- Meng Pan (ORCID: https://orcid.org/0000-0003-4947-9369)
- Congxin Liang
- Wen-Hao Yin
Institutions
- nLIGHT (United States) (US)
- Harbin Medical University (CN)
- Wenzhou Medical University (CN)
- Ruijin Hospital (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Wuhan University (CN)
- Shanghai Stomatological Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
- First Hospital of Jiaxing (CN)
- Renmin Hospital of Wuhan University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Southern Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1093/bjd/ljaf185
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.39